Bora Biologics
Private Company
Funding information not available
Overview
Bora Biologics is a U.S.-based CDMO founded in 2014, focused on late-stage and commercial-scale biologics manufacturing. It boasts a strong track record with over 50 biologic programs advanced, 100 cGMP batches delivered, and has successfully commercialized a biosimilar in the U.S. and Canada. The company leverages state-of-the-art facilities and a team of over 125 experts to provide integrated development, manufacturing, and quality services. Its business model is built on providing tailored, collaborative CDMO solutions to biopharma clients.
Technology Platform
Integrated mammalian and microbial process development and GMP manufacturing platform, featuring high-throughput screening, advanced analytics, formulation development, and commercial-scale production suites.
Opportunities
Risk Factors
Competitive Landscape
Bora Biologics competes in a crowded and competitive global biologics CDMO market against large, established players like Lonza, Samsung Biologics, and Fujifilm Diosynth, as well as other U.S.-based specialists. Its key differentiators are its focused commercial-scale capabilities in the U.S., proven biosimilar expertise, and integrated mammalian/microbial offerings, but it must contend with competitors who have greater scale, broader geographic footprints, and more extensive service portfolios.